Voluntary nationwide recall: Clonazepam (Endo – July)
Sep. 2024Pharmacy Updates
Endo USA Inc. has recalled one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.25 mg. Clonazepam is used to treat panic disorder and certain seizures.
This product is being recalled because the cartons of some packs show the product strength as 0.125 mg, not 0.25 mg, due to an error at a third-party packager. The blister strips inside the product pack reflect the correct strength of 0.25 mg.
Using this drug at a higher dose than prescribed may cause sleepiness, dizziness, loss of muscle control, and confusion.
As of July 16, there had been no reports of adverse events related to this recall.
To learn more about this recall:
- Call Inmar Inc. at 1-877-890-0765. Help is available Monday through Friday from 9 a.m. to 5 p.m. ET.
- Visit the FDA website.
Recent Announcements
Asymptomatic Severe Coronary Disease: Detection to Decisions. Do We Know The Proper Management?
In this new CME course, Krishna V. Tummalapalli, MD, interventional cardiologist, UPMC Heart and Vascular Institute, discusses how to explain the importance of early detection of coronary artery disease, as well as how to describe how early identification can reduce future cardiovascular events and identify appropriate first line medical therapy strategies for patients with asymptomatic stable ischemic heart disease.Mar. 2026Education/Webinars
CME Webinar Series: Introducing Physicians and their teams to Value-Based Health Care
Please join us for a new CME-accredited webinar series on value-based care. This series is designed to introduce practicing physicians and their teams to value-based health care. Over the course of six sessions, we will define the components of value and identify the tools necessary to deliver high-value care for a population.Feb. 2026Education/Webinars